Opus Genetics shares early gene‑therapy trial outcomes and plans Phase 3 start
Opus Genetics reported interim results from its OPGx‑BEST1 and OPGx‑LCA5 programs at a retinal conference in Rio. Adults treated with OPGx‑LCA5 showed lasting gains in visual acuity and light sensitivity for up to two years, while pediatric participants improved for six months. The low‑dose cohort of OPGx‑BEST1 demonstrated better retinal sensitivity in three of four assessable patients. The company said Phase 3 dosing for OPGx‑LCA5 is slated for the fourth quarter of 2026.
Why it matters
The data suggest the therapies are delivering functional vision improvements, which could increase investor confidence ahead of the Phase 3 launch (the company indicated this expectation). The upcoming Phase 3 dosing may trigger further market attention and potential valuation uplift if results remain positive (company statement).
Key facts
- 1Adults in the OPGx‑LCA5 study maintained improved visual acuity and light sensitivity for 24 months. stocktitan.net
- 2Three pediatric participants showed vision gains lasting six months in the same study. stocktitan.net
- 3OPGx‑BEST1 produced enhanced retinal sensitivity in three of four evaluable participants. investing.com
- 4Phase 3 dosing for OPGx‑LCA5 is expected in Q4 2026. stocktitan.net
- 5Enrollment for the high‑dose cohort of OPGx‑BEST1 has been completed with 11 participants. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.